Brooke Army Medical Center, Department of General Surgery, 3851 Roger Brooke Drive, Ft. Sam Houston, TX 78234, USA.
Expert Opin Biol Ther. 2011 Nov;11(11):1543-50. doi: 10.1517/14712598.2011.616889. Epub 2011 Sep 6.
Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8(+) T-cell-eliciting vaccines. AE37 is a promising primarily CD4(+) T-cell-eliciting HER-2/neu breast cancer vaccine currently in clinical trials.
This article reviews preclinical investigations as well as findings from completed and ongoing Phase I and Phase II clinical trials of the AE37 vaccine.
Clinical trials have shown the AE37 vaccine to be safe and capable of generating peptide-specific, durable immune responses. This has been shown in patients with any level of HER-2/neu expression. Early clinical findings suggest there may be benefit to AE37 vaccination in preventing breast cancer recurrence.
免疫疗法，包括针对人类 EGFR2（HER-2/neu）蛋白的疫苗，是抗击乳腺癌的一个活跃研究领域。目前有几种疫苗正在进行临床试验，其中大多数是 CD8(+) T 细胞激发疫苗。AE37 是一种有前途的主要激发 CD4(+) T 细胞的 HER-2/neu 乳腺癌疫苗，目前正在临床试验中。
本文综述了 AE37 疫苗的临床前研究以及已完成和正在进行的 I 期和 II 期临床试验的结果。
临床试验表明，AE37 疫苗是安全的，并能够产生针对肽的持久免疫反应。这在 HER-2/neu 表达水平任意的患者中都得到了证实。早期临床发现表明，AE37 疫苗接种可能有助于预防乳腺癌复发。
